Table 1.
Summary of patients’ characteristics.
| Counts (%) | Median | Range | ||
|---|---|---|---|---|
| Age | 52 | 31–73 | ||
| Sex | ||||
| Male | 9 (15.8) | |||
| Female | 48 (84.2) | |||
| Smoking | ||||
| Yes | 4 (16.9) | |||
| No | 53 (83.1) | |||
| Drinking | ||||
| Yes | 1 (3.1) | |||
| No | 56 (96.9) | |||
| Family history | ||||
| Yes | 11 (21.5) | |||
| No | 46 (78.5) | |||
| COPD | ||||
| Mild | 2 (9.2) | |||
| No | 55 (89.2) | |||
| Lung function | ||||
| FEV1 | 2.43 | 1.26–3.89 | ||
| FEV1% | 102.4 | 83.4–139.4 | ||
| FEV1/FVC ratio | 0.75 | 0.65–0.90 | ||
| CEA | 1.25 | 0.5–4.12 | ||
| NSE | 12.62 | 8.63–24.33 | ||
| CYFRA21-1 | 1.98 | 0.81–6.30 | ||
| SCC | 0.70 | 0.3–2.70 | ||
| proGRP | 40.9 | 13.55–77.6 | ||
| VATs time (min) | 170 | 70–320 | ||
COPD, chronic obstructive pulmonary disease; CEA, carcinoembryonic antigen; NSE, neuron-specific enolase; CYFRA21-1, cytokeratin 19 fragment; SCC, small-cell carcinoma; proGRP, progastrin-releasing peptide.